[1] | Stanley SL Jr. Amoebiasis. Lancet. 2003;361(9362):1025–34. Epub 2003/03/28. pmid:12660071 doi: 10.1016/s0140-6736(03)12830-9
|
[2] | Ximénez C, Morán P, Rojas L, Valadez A, Gómez A. Reassessment of the epidemiology of amebiasis: state of the art. Infect Genet Evol. 2009;9(6):1023–32. doi: 10.1016/j.meegid.2009.06.008. pmid:19540361
|
[3] | Wertheim HF, Horby P, Woodall JP. Atlas of human infectious diseases. UK: Blackwell Publishing; 2012.
|
[4] | Walsh JA. Problems in recognition and diagnosis of amebiasis: estimation of the global magnitude of morbidity and mortality. Rev Infect Dis. 1986;8(2):228–38. pmid:2871619 doi: 10.1093/clinids/8.2.228
|
[5] | Abd Alla MD, Wolf R, White GL, Kosanke SD, Cary D, Verweij JJ, et al. Efficacy of a Gal-lectin subunit vaccine against experimental Entamoeba histolytica infection and colitis in baboons (Papio sp.). Vaccine. 2012;30(20):3068–75. doi: 10.1016/j.vaccine.2012.02.066. pmid:22406457
|
[6] | Chebolu S, Daniell H. Stable expression of Gal/GalNAc lectin of Entamoeba histolytica in transgenic chloroplasts and immunogenicity in mice towards vaccine development for amoebiasis. Plant Biotechnol J. 2007;5(2):230–9. pmid:17309678 doi: 10.1111/j.1467-7652.2006.00234.x
|
[7] | Lotter H, Russmann H, Heesemann J, Tannich E. Attenuated recombinant Yersinia as live oral vaccine carrier to protect against amoebiasis. Int J Med Microbiol. 2008;298(1–2):79–86. pmid:17900982 doi: 10.1016/j.ijmm.2007.07.001
|
[8] | Barroso L, Abhyankar M, Noor Z, Read K, Pedersen K, White R, et al. Expression, purification, and evaluation of recombinant LecA as a candidate for an amebic colitis vaccine. Vaccine. 2014;32(10):1218–24. doi: 10.1016/j.vaccine.2013.06.056. pmid:23827311
|
[9] | Ivory CP, Keller K, Chadee K. CpG-oligodeoxynucleotide is a potent adjuvant with an Entamoeba histolytica Gal-inhibitable lectin vaccine against amoebic liver abscess in gerbils. Infect Immun. 2006;74(1):528–36. pmid:16369009 doi: 10.1128/iai.74.1.528-536.2006
|
[10] | Guo X, Barroso L, Becker SM, Lyerly DM, Vedvick TS, Reed SG, et al. Protection against intestinal amebiasis by a recombinant vaccine is transferable by T cells and mediated by gamma interferon. Infect Immun. 2009;77(9):3909–18. doi: 10.1128/IAI.00487-09. pmid:19564375
|
[11] | Guo X, Barroso L, Lyerly DM, Petri WA Jr., Houpt ER. CD4+ and CD8+ T cell- and IL-17-mediated protection against Entamoeba histolytica induced by a recombinant vaccine. Vaccine. 2011;29(4):772–7. doi: 10.1016/j.vaccine.2010.11.013. pmid:21095257
|
[12] | Teixeira JE, Huston CD. Participation of the serine-rich Entamoeba histolytica protein in amebic phagocytosis of apoptotic host cells. Infect Immun. 2008;76(3):959–66. pmid:18086807 doi: 10.1128/iai.01455-07
|
[13] | Lotter H, Tannich E. The current status of an amebiasis vaccine. Arch Med Res. 2006;37(2):292–6. pmid:16380335 doi: 10.1016/j.arcmed.2005.09.004
|
[14] | Gonzalez-Vazquez MC, Carabarin-Lima A, Baylon-Pacheco L, Talamas-Rohana P, Rosales-Encina JL. Obtaining of three recombinant antigens of Entamoeba histolytica and evaluation of their immunogenic ability without adjuvant in a hamster model of immunoprotection. Acta Trop. 2012;122(2):169–76. doi: 10.1016/j.actatropica.2011.12.007. pmid:22266120
|
[15] | Melzer H, Fortugno P, Mansouri E, Felici F, Marinets A, Wiedermann G, et al. Antigenicity and immunogenicity of phage library-selected peptide mimics of the major surface proteophosphoglycan antigens of Entamoeba histolytica. Parasite Immunol. 2002;24(6):321–8. pmid:12102717 doi: 10.1046/j.1365-3024.2002.00463.x
|
[16] | Zhang Z, Duchene M, Stanley SL Jr. A monoclonal antibody to the amebic lipophosphoglycan-proteophosphoglycan antigens can prevent disease in human intestinal xenografts infected with Entamoeba histolytica. Infect Immun. 2002;70(10):5873–6. pmid:12228321 doi: 10.1128/iai.70.10.5873-5876.2002
|
[17] | Teixeira JE, Sateriale A, Bessoff KE, Huston CD. Control of Entamoeba histolytica adherence involves metallosurface protease 1, an M8 family surface metalloprotease with homology to leishmanolysin. Infect Immun. 2012;80(6):2165–76. doi: 10.1128/IAI.06389-11. pmid:22451519
|
[18] | Roncolato EC, Teixeira JE, Barbosa JE, Zambelli Ramalho LN, Huston CD. Immunization with the Entamoeba histolytica surface metalloprotease EhMSP-1 protects hamsters from amebic liver abscess. Infect Immun. 2015;83(2):713–20. doi: 10.1128/IAI.02490-14. pmid:25452550
|
[19] | Petri WA Jr., Haque R, Mann BJ. The bittersweet interface of parasite and host: lectin-carbohydrate interactions during human invasion by the parasite Entamoeba histolytica. Annu Rev Microbiol. 2002;56:39–64. pmid:12142490 doi: 10.1146/annurev.micro.56.012302.160959
|
[20] | Petri WA Jr., Schnaar RL. Purification and characterization of galactose- and N-acetylgalactosamine-specific adhesin lectin of Entamoeba histolytica. Methods Enzymol. 1995;253:98–104. pmid:7476421 doi: 10.1016/s0076-6879(95)53011-8
|
[21] | Lopez-Vancell R, Montfort I, Perez-Tamayo R. Galactose-specific adhesin and cytotoxicity of Entamoeba histolytica. Parasitol Res. 2000;86(3):226–31. pmid:10726993 doi: 10.1007/s004360050035
|
[22] | Cheng XJ, Tsukamoto H, Kaneda Y, Tachibana H. Identification of the 150-kDa surface antigen of Entamoeba histolytica as a galactose- and N-acetyl-D-galactosamine-inhibitable lectin. Parasitol Res. 1998;84(8):632–9. pmid:9747935 doi: 10.1007/s004360050462
|
[23] | Cheng XJ, Kaneda Y, Tachibana H. A monoclonal antibody against the 150-kDa surface antigen of Entamoeba histolytica inhibits adherence and cytotoxicity to mammalian cells. Medical Science Research. 1997;25(3):159–61.
|
[24] | Tachibana H, Takekoshi M, Cheng XJ, Maeda F, Aotsuka S, Ihara S. Bacterial expression of a neutralizing mouse monoclonal antibody Fab fragment to a 150-kilodalton surface antigen of Entamoeba histolytica. The American journal of tropical medicine and hygiene. 1999;60(1):35–40. pmid:9988319
|
[25] | Cheng XJ, Tachibana H, Kaneda Y. Protection of hamsters from amebic liver abscess formation by a monoclonal antibody to a 150-kDa surface lectin of Entamoeba histolytica. Parasitol Res. 1999;85(1):78–80. pmid:9950232 doi: 10.1007/s004360050510
|
[26] | Cheng XJ, Tachibana H. Protection of hamsters from amebic liver abscess formation by immunization with the 150- and 170-kDa surface antigens of Entamoeba histolytica. Parasitol Res. 2001;87(2):126–30. pmid:11206109 doi: 10.1007/s004360000323
|
[27] | Cheng XJ, Hughes MA, Huston CD, Loftus B, Gilchrist CA, Lockhart LA, et al. Intermediate subunit of the Gal/GalNAc lectin of Entamoeba histolytica is a member of a gene family containing multiple CXXC sequence motifs. Infect Immun. 2001;69(9):5892–8. pmid:11500468 doi: 10.1128/iai.69.9.5892-5898.2001
|
[28] | McCoy JJ, Mann BJ. Proteomic analysis of Gal/GalNAc lectin-associated proteins in Entamoeba histolytica. Exp Parasitol. 2005;110(3):220–5. pmid:15955316 doi: 10.1016/j.exppara.2005.02.013
|
[29] | Tachibana H, Cheng XJ, Kobayashi S, Okada Y, Itoh J, Takeuchi T. Primary structure, expression and localization of two intermediate subunit lectins of Entamoeba dispar that contain multiple CXXC motifs. Parasitology. 2007;134(Pt.14):1989–99. pmid:17803840 doi: 10.1017/s0031182007003459
|
[30] | Tachibana H, Cheng XJ, Masuda G, Horiki N, Takeuchi T. Evaluation of recombinant fragments of Entamoeba histolytica Gal/GalNAc lectin intermediate subunit for serodiagnosis of amebiasis. Journal of clinical microbiology. 2004;42(3):1069–74. Epub 2004/03/09. pmid:15004055 doi: 10.1128/jcm.42.3.1069-1074.2004
|
[31] | Tachibana H, Cheng XJ, Tsukamoto H, Itoh J. Characterization of Entamoeba histolytica intermediate subunit lectin-specific human monoclonal antibodies generated in transgenic mice expressing human immunoglobulin loci. Infect Immun. 2009;77(1):549–56. doi: 10.1128/IAI.01002-08. pmid:19001071
|
[32] | Kobayashi S, Imai E, Haghighi A, Khalifa SA, Tachibana H, Takeuchi T. Axenic cultivation of Entamoeba dispar in newly designed yeast extract-iron-gluconic acid-dihydroxyacetone-serum medium. J Parasitol. 2005;91(1):1–4. Epub 2005/04/29. pmid:15856863 doi: 10.1645/ge-3386
|
[33] | Ravdin JI, Guerrant RL. Role of adherence in cytopathogenic mechanisms of Entamoeba histolytica. Study with mammalian tissue culture cells and human erythrocytes. J Clin Invest. 1981;68(5):1305–13. pmid:6271810 doi: 10.1172/jci110377
|
[34] | Schifferli JA, Woo P, Peters DK. Complement-mediated inhibition of immune precipitation. I. Role of the classical and alternative pathways. Clinical and experimental immunology. 1982;47(3):555–62. pmid:6979442 doi: 10.1016/0161-5890(82)90144-4
|
[35] | Hamelmann C, Foerster B, Burchard GD, Horstmann RD. Lysis of pathogenic and nonpathogenic Entamoeba histolytica by human complement: methodological analysis. Parasite immunology. 1992;14(1):23–35. pmid:1557228 doi: 10.1111/j.1365-3024.1992.tb00003.x
|
[36] | Faisal SM, Yan W, Chen CS, Palaniappan RU, McDonough SP, Chang YF. Evaluation of protective immunity of Leptospira immunoglobulin like protein A (LigA) DNA vaccine against challenge in hamsters. Vaccine. 2008;26(2):277–87. pmid:18055070 doi: 10.1016/j.vaccine.2007.10.029
|
[37] | Vernel-Pauillac F, Goarant C. Differential cytokine gene expression according to outcome in a hamster model of leptospirosis. PLoS neglected tropical diseases. 2010;4(1):e582. doi: 10.1371/journal.pntd.0000582. pmid:20076757
|
[38] | Choudhuri G, Prakash V, Kumar A, Shahi SK, Sharma M. Protective immunity to Entamoeba histolytica infection in subjects with antiamoebic antibodies residing in a hyperendemic zone. Scand J Infect Dis. 1991;23(6):771–6. pmid:1815341 doi: 10.3109/00365549109024306
|
[39] | Haque R, Mondal D, Duggal P, Kabir M, Roy S, Farr BM, et al. Entamoeba histolytica infection in children and protection from subsequent amebiasis. Infect Immun. 2006;74(2):904–9. pmid:16428733 doi: 10.1128/iai.74.2.904-909.2006
|
[40] | Stanley SL Jr. Progress towards development of a vaccine for amebiasis. Clin Microbiol Rev. 1997;10(4):637–49. pmid:9336666
|
[41] | Huston CD, Petri WA Jr. Host-pathogen interaction in amebiasis and progress in vaccine development. Eur J Clin Microbiol Infect Dis. 1998;17(9):601–14. pmid:9832261 doi: 10.1007/bf01708342
|
[42] | Quach J, St-Pierre J, Chadee K. The future for vaccine development against Entamoeba histolytica. Human vaccines & immunotherapeutics. 2014;10(6):1514–21. doi: 10.4161/hv.27796
|
[43] | Lotter H, Zhang T, Seydel KB, Stanley SL Jr., Tannich E. Identification of an epitope on the Entamoeba histolytica 170-kD lectin conferring antibody-mediated protection against invasive amebiasis. J Exp Med. 1997;185(10):1793–801. pmid:9151705 doi: 10.1084/jem.185.10.1793
|
[44] | Meneses-Ruiz DM, Laclette JP, Aguilar-Diaz H, Hernandez-Ruiz J, Luz-Madrigal A, Sampieri A, et al. Mucosal delivery of ACNPV baculovirus driving expression of the Gal-lectin LC3 fragment confers protection against amoebic liver abscess in hamster. Int J Biol Sci. 2011;7(9):1345–56. pmid:22110386 doi: 10.7150/ijbs.7.1345
|
[45] | Campbell D, Chadee K. Interleukin (IL)-2, IL-4, and tumor necrosis factor-a responses during Entamoeba histolytica liver abscess development in gerbils. J Infect Dis. 1997;175(5):1176–83. pmid:9129082 doi: 10.1086/520355
|
[46] | Tsutsumi V, Mena-Lopez R, Anaya-Velazquez F, Martinez-Palomo A. Cellular bases of experimental amebic liver abscess formation. Am J Pathol. 1984;117(1):81–91. pmid:6385728
|
[47] | Guo X, Stroup SE, Houpt ER. Persistence of Entamoeba histolytica infection in CBA mice owes to intestinal IL-4 production and inhibition of protective IFN-gamma. Mucosal Immunol. 2008;1(2):139–46. doi: 10.1038/mi.2007.18. pmid:19079171
|
[48] | Helk E, Bernin H, Ernst T, Ittrich H, Jacobs T, Heeren J, Tacke F, Tannich E, Lotter H. TNFα-mediated liver destruction by Kupffer cells and Ly6Chi monocytes during Entamoeba histolytica infection. PLoS Pathog. 2013;9(1):e1003096. doi: 10.1371/journal.ppat.1003096. pmid:23300453
|
[49] | Moonah SN, Jiang NM, Petri WA Jr. Host immune response to intestinal amebiasis. PLoS Pathog. 2013;9(8):e1003489. doi: 10.1371/journal.ppat.1003489. pmid:23990778
|
[50] | Keir ME, Francisco LM, Sharpe AH. PD-1 and its ligands in T-cell immunity. Current opinion in immunology. 2007;19(3):309–14. pmid:17433872 doi: 10.1016/j.coi.2007.04.012
|
[51] | Hawkes EA, Grigg A, Chong G. Programmed cell death-1 inhibition in lymphoma. The Lancet Oncology. 2015;16(5):e234–e45. doi: 10.1016/S1470-2045(15)70103-8. pmid:25943068
|
[52] | Shen C, Hupin C, Froidure A, Detry B, Pilette C. Impaired ICOSL in human myeloid dendritic cells promotes Th2 responses in patients with allergic rhinitis and asthma. Clin Exp Allergy. 2014;44(6):831–41. doi: 10.1111/cea.12308. pmid:24661627
|
[53] | Chaudhry OA, Petri WA Jr. Vaccine prospects for amebiasis. Expert Rev Vaccines. 2005;4(5):657–68. pmid:16221067 doi: 10.1586/14760584.4.5.657
|
[54] | Visvanathan K, Lewin SR. Immunopathogenesis: role of innate and adaptive immune responses. Semin Liver Dis. 2006;26(2):104–15. pmid:16673289 doi: 10.1055/s-2006-939755
|
[55] | Mosmann TR, Coffman RL. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annual review of immunology. 1989;7:145–73. pmid:2523712 doi: 10.1146/annurev.immunol.7.1.145
|